ABSTRACT
A case of familial clustering of interstitial cystitis (IC) and chronic pelvic pain syndrome (CPPS), a symptom complex similar to IC that occurs in men, is reported. The proband was a 28-year-old woman with a 6-month history of severe frequency, urgency, and genital pain. After cystoscopy with hydrodistention and biopsy, a diagnosis of IC was made. IC was also diagnosed in the patient's mother and in two of her brothers, previously considered to have CPPS (category IIIB CPPS). A third brother was asymptomatic. This case highlights the importance of genetic factors in the onset of symptoms and natural history of IC and CPPS.
Subject(s)
Cystitis, Interstitial/diagnosis , Cystitis, Interstitial/genetics , Pelvic Pain/genetics , Adult , Biopsy , Chronic Disease , Cystitis, Interstitial/complications , Cystoscopy , Female , Humans , Male , Pedigree , SyndromeABSTRACT
The authors draw attention to the possibility that some of the equivocal cases of internal diseases diagnosed variously and treated in various hospitals may actually be caused by Chlamydia trachomatis or other species of the genus Chlamydia. We report a case of a generalized chlamydia infection which brought about multiple lesions. The etiologic differentiation of the disorder in the present case was made possible only through using the method of polymerase chain reaction to identify the Chlamydia trachomatis agent.
Subject(s)
Chlamydia Infections/diagnosis , Chlamydia Infections/virology , Chlamydia trachomatis/isolation & purification , Polymerase Chain Reaction , Adult , Humans , MaleABSTRACT
UNLABELLED: In the study a clinical assessment is made of the results of treatment of patients with renal anemia by epoetin-beta. MATERIAL AND METHODS: Thirty two patients (22 women, 10 men) with chronic renal failure and anemia, ranging from 18 to 77 years of age (mean age 46.29 +/- 5.84), were recruited for the study. All patients underwent treatment with epoetin-beta (Recormon, Boehringer-La Roche). The criterion for inclusion in the study was presence of severe anemia (HGB < 90 g/l). Extrarenal causes for the anemia were excluded in all patients. The main treatment objective was to increase hemoglobin to 100-120 g/l. All patients received concomitant iron supplementation at constant control of the iron status. The predialysis patients were administered iron perorally (200 mg/day) while the patients on chronic hemodialysis were given iron parenterally (intravenously) (Venofer, 100 mg/day). RESULTS: Anemia was significantly corrected. Hemoglobin level rose significantly from 77.15 +/- 2.32 g/l before treatment to 110.71 +/- 6.25 g/l at the end of month three. It remained less than 100 g/l for the time of study only in one patient. Neo-Recormon had a considerable positive effect on the overall condition of patients. No significant changes were found in the rate of progression of renal failure nor were there any marked side effects and intolerability to the drug observed. CONCLUSIONS: Anemia was significantly corrected in the renal anemia patients treated with epoetin beta. In predialysis patients iron supplementation can be effectively administered orally. If given in high doses (more than 4000 IU/kg), epoetin-beta can cause rapid increase of the hematologic parameters, especially in the initial phase of treatment; this affects adversely arterial pressure which necessitates changes in the antihypertensive therapy. Erythropoietin therapy reduces and even eliminates the need of transfusion in patients with chronic renal anemia.